Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study-Reference-Cited by-同舟云学术

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Published:2017-10-19 Issue:16 Volume:130 Page:1800-1808
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Crump Michael¹,Neelapu Sattva S.²,Farooq Umar³,Van Den Neste Eric⁴,Kuruvilla John¹,Westin Jason²,Link Brian K.³,Hay Annette¹,Cerhan James R.⁵,Zhu Liting¹,Boussetta Sami⁴,Feng Lei²,Maurer Matthew J.⁵,Navale Lynn⁶,Wiezorek Jeff⁶,Go William Y.⁶,Gisselbrecht Christian⁴

Affiliation:

1. Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada;

2. Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX;

3. Division of Hematology, Oncology, and Blood and Marrow Transplantation, Department of Internal Medicine, University of Iowa, Iowa City, IA;

4. Lymphoma Academic Research Organization, Pierre-Bénite, France;

5. Department of Health Sciences Research, Mayo Clinic, Rochester, MN; and

6. Kite Pharma, Santa Monica, CA

Abstract

Key Points SCHOLAR-1 is the first patient-level analysis of outcomes of refractory DLBCL from 2 large randomized trials and 2 academic databases. SCHOLAR-1 demonstrated poor outcomes in patients with refractory DLBCL, supporting a need for more effective therapies for these patients.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/16/1800/1402936/blood769620.pdf

Reference37 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes [published online ahead of print 12 September 2016];Teras;CA Cancer J Clin

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2012

3. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study;Sant;Lancet Oncol,2014

Cited by 1067 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

2. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas;Expert Opinion on Biological Therapy;2024-02-02

3. Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis;Advances in Therapy;2024-02-02

4. CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Brutonʼs Tyrosine Kinase Inhibition;Journal of Clinical Oncology;2024-02-01

5. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study;The Lancet Haematology;2024-02